SAR-445710 is under clinical development by Kadmon Holdings and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SAR-445710’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SAR-445710 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SAR-445710 overview

KD-033 is under development for the treatment of metastatic solid tumors, lung cancer, melanoma and colon cancer. The drug candidate is a chimera, a bi-functional fusion protein comprised of anti-PD-L1 antibody linked at its tail to the cytokine IL-15 by the sushi domain of the IL-15 receptor. It is administered through intravenous route.

Kadmon Holdings overview

Kadmon Holdings (Kadmon) is an integrated biopharmaceutical company that discovers, develops and markets small molecules and biologics for autoimmune and fibrotic diseases, various types of cancer, and genetic diseases. The company’s pipeline encompasses investigational candidates for the treatment of moderate to severe psoriasis, idiopathic pulmonary fibrosis, and polycystic kidney disease among others. Its pipeline candidates are based on its small molecule and biologics platforms. It also develops in-licensed product candidates and technologies. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline candidates. Kadmon is headquartered in New York, the US.

Quick View SAR-445710 LOA Data

Report Segments
  • Innovator
Drug Name
  • SAR-445710
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.